Skip to main content

Table 1 Baseline Demographics and Clinical Characteristics for Patients Treated with Talimogene Laherparepvec and GM-CSF

From: Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Characteristics

All Patientsa(N = 436)

Patients with Durable Response (N = 51)

Median age (range), years

63 (22–94)

70 (36–91)

Sex, n (%)

 Men

250 (57)

31 (61)

 Women

186 (43)

20 (39)

Disease substage, n (%)b

 IIIB

34 (8)

10 (20)

 IIIC

97 (22)

19 (37)

 IVM1a

118 (27)

13 (26)

 IVM1b

90 (21)

3 (6)

 IVM1c

96 (22)

6 (12)

 Missing

1 (<1)

0 (0)

LDH, n (%)a

 ≤ ULN

390 (89)

47 (92)

 > ULN

20 (5)

0 (0)

Line of therapy, n (%)

 First-line

203 (47)

33 (65)

 Second or greater

233 (53)

18 (35)

ECOG performance status, n (%)a

 0

306 (70)

41 (80)

 1

114 (26)

10 (20)

 Missing

16 (4)

0 (0)

HSV serostatus, n (%)a

 Positive

142 (33)

34 (67)

 Negative

253 (58)

13 (26)

 Unknown/missing

41 (9)

4 (8)

BRAF status, n (%)

 Mutation

69 (16)

5 (10)

 Wild-type

68 (16)

6 (12)

 Unknown/missing

299 (68)

40 (78)

Treatment assignment, n (%)

 Talimogene laherparepvecc

295 (68)

48 (94)

 GM-CSFd

141 (32)

3 (6)

  1. DRR durable response rate, ECOG Eastern Cooperative Oncology Group, GM-CSF granulocyte macrophage-colony stimulating factor, HSV herpes simplex virus, LDH lactate dehydrogenase, ULN upper limit of normal
  2. aIntent-to-treat population
  3. bIncludes one patient with unknown disease stage
  4. c4 patients in the talimogene laherparepvec arm were not treated with talimogene laherparepvec
  5. d11 patients in the GM-CSF arm were not treated with GM-CSF